ADC Therapeutics S.A. (ADCT) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 6.56
30Y Low3.8·High9.3
ROE
↓
N/A
—
5yr avg: -109.9%
30Y Low-128%·High-36%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ADCT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ADC Therapeutics S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $139M | $449M | $193M | $136M | $300M | $1.6B | $2.1B | — | — | — |
| Enterprise Value | $316M | $626M | $65M | $-18578804 | $104M | $1.2B | $1.8B | — | — | — |
| P/E Ratio → | -0.97 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.70 | 5.51 | 2.73 | 1.95 | 1.43 | 45.71 | — | — | — | — |
| P/B Ratio | — | — | — | — | 3.78 | 9.33 | 6.24 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ADCT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.70 | 0.92 | -0.27 | 0.49 | 36.07 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
ADCT Profitability
Margins and return-on-capital ratios measuring operating efficiency
ADC Therapeutics S.A. earns an operating margin of -133.2%. Operating margins have expanded from -238.6% to -133.2% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.6% | 90.6% | 91.6% | 96.4% | 98.4% | 95.9% | — | 100.0% | -10258.4% | -4643.8% |
| Operating Margin | -133.2% | -133.2% | -184.4% | -238.6% | -58.8% | -771.6% | — | -5102.5% | -11047.5% | -5084.3% |
| Net Profit Margin | -175.3% | -175.3% | -222.8% | -345.1% | -74.9% | -678.2% | — | -4977.9% | -10797.9% | -4984.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -128.0% | -91.7% | -110.3% | -98.1% | -65.6% | -36.1% |
| ROA | -44.2% | -44.2% | -46.6% | -56.8% | -28.3% | -40.7% | -75.6% | -80.8% | -58.3% | -33.0% |
| ROIC | — | — | — | — | — | — | -2734.6% | -14080.1% | — | — |
| ROCE | -43.8% | -43.8% | -49.4% | -47.7% | -25.9% | -51.5% | -74.2% | -97.1% | -66.4% | -36.5% |
ADCT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $178M ($439M total debt minus $261M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 1.63 | 0.84 | 0.34 | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -2.47 | -1.97 | -0.97 | -0.99 | -1.10 | -1.05 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.10 | -2.10 | -2.11 | -3.22 | -3.00 | -12.71 | -44.47 | -741.96 | — | — |
ADCT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
ADC Therapeutics S.A.'s current ratio of 4.37x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.97x to 4.37x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.37 | 4.37 | 3.82 | 4.97 | 5.31 | 7.10 | 11.14 | 6.15 | 6.36 | 12.91 |
| Quick Ratio | 4.31 | 4.31 | 3.59 | 4.73 | 5.16 | 6.95 | 11.14 | 6.15 | 6.30 | 12.89 |
| Cash Ratio | 3.72 | 3.72 | 3.12 | 4.12 | 3.98 | 6.31 | 10.86 | 5.79 | 6.21 | 12.79 |
| Asset Turnover | — | 0.25 | 0.22 | 0.20 | 0.43 | 0.05 | — | 0.02 | 0.01 | 0.01 |
| Inventory Turnover | 1.83 | 1.83 | 0.32 | 0.16 | 0.27 | 0.13 | — | — | 98.08 | 291.91 |
| Days Sales Outstanding | — | 130.63 | 104.68 | 132.14 | 126.89 | 346.16 | — | 442.99 | 119.11 | 390.10 |
ADCT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ADC Therapeutics S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $127M | $97M | $82M | $78M | $77M | $65M | $67M | $54M | $59M |
Peer Comparison
Compare ADCT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ADCTYou | $139M | -1.0 | — | — | 90.6% | -133.2% | — | — | — |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 MGNX | $263M | -3.5 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 AIXI | $3M | -0.0 | — | — | 44.4% | -783.6% | — | — | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 BCYC | $277M | -1.3 | — | — | 100.0% | -341.3% | -31.2% | — | — |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARVN | $495M | -6.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ADCT — Frequently Asked Questions
Quick answers to the most common questions about buying ADCT stock.
What is ADC Therapeutics S.A.'s P/E ratio?
ADC Therapeutics S.A.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
Is ADCT stock overvalued?
Based on historical data, ADC Therapeutics S.A. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are ADC Therapeutics S.A.'s profit margins?
ADC Therapeutics S.A. has 90.6% gross margin and -133.2% operating margin.